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Urinary tract infections (UTIs), the majority of which are caused by uropathogenic Escherichia coli
(UPEC), afflict nearly 60% of women within their lifetimes. Studies in mice and humans have revealed that
UPEC strains undergo a complex pathogenesis cycle that involves both the formation of intracellular
bacterial communities (IBC) and the colonization of extracellular niches. Despite the commonality of the
UPEC pathogenesis cycle, no specific urovirulence genetic profile has been determined; this is likely due
to the fluid nature of the UPEC genome as the result of horizontal gene transfer and numerous genes of
unknown function. UTI89 has a large extrachromosomal element termed pUTI89 with many character-
istics of UPEC pathogenicity islands and that likely arose due to horizontal gene transfer. The pUTI89
plasmid has characteristics of both F plasmids and other known virulence plasmids. We sought to
determine whether pUTI89 is important for virulence. Both in vitro and in vivo assays were used to examine
the function of pUTI89 using plasmid-cured UTI89. No differences were observed between UTI89 and
plasmid-cured UTI89 based on growth, type 1 pilus expression, or biofilm formation. However, in a mouse
model of UTI, a significant decrease in bacterial invasion, CFU and IBC formation of the pUTI89-cured
strain was observed at early time points postinfection compared to the wild type. Through directed
deletions of specific operons on pUTI89, the cjr operon was partially implicated in this observed defect.
Our findings implicate pUTI89 in the early aspects of infection.
Urinary tract infections (UTIs) represent, by number, one of
the most important bacterial infectious diseases in highly in-
dustrialized countries (20). Sixty-percent of all women will
have at least one UTI within their lifetime (21, 57, 63). This
infection results in nearly 7 million physician office visits and
$3.5 billion dollars annually in the United States alone (19). It
is thought that acute UTIs develop when bacteria from the
fecal flora colonize the vaginal and periurethral mucosa and
are subsequently introduced into the bladder by urethral as-
cension. Women who present with an initial episode of acute
UTI have a 25 to 44% chance of developing a second and a 3%
chance of experiencing three episodes within 6 months of the
initial UTI (20). Recurrence occurs despite appropriate anti-
biotic treatment and clearance of the initial infection from the
urine. A large percentage of recurrent UTI are caused by the
same strain of bacteria as the initial infection (65). The high
frequency of same-strain recurrences supports the notion that
a UPEC reservoir may exist in the affected individual.
Uropathogenic Escherichia coli (UPEC) is the leading caus-
ative agent of UTI, responsible for up to 85% of community-
acquired UTI and 25% of nosocomial UTI (62). Using a well-
characterized clinical UPEC isolate, UTI89, in a mouse cystitis
model, it has been demonstrated that the pathogenesis of UTI
involves intracellular and extracellular components (34, 35,
47). The bladder surface is covered with a urothelium com-
posed of very large superficial umbrella cells which are coated
with uroplakins that expose a terminal mannose moiety (77).
Type 1 pili and its adhesin, FimH, are required for attachment
and invasion, thus playing a critical role in the infection process
(47, 50, 76). The FimH protein has a negatively charged pocket
that accommodates a mannose unit, namely, those exposed by
uroplakins on the bladder surface (28). In addition to man-
nose, it was shown that FimH binds 31 integrin subunits
expressed by bladder epithelial cells mediating uptake of
UPEC (18). Integrins link extracellular matrix proteins with
the actin cytoskeleton and can initiate a signaling cascade re-
sulting in bacterial internalization (46, 47). Invasion of UPEC
also involves cellular lipid raft components, including uro-
plakin 1a, caveolin-1, and Rac-1, and internalized bacteria are
retained within compartments resembling fusiform vesicles (6,
17). After invasion, bladder epithelial cells are capable of ex-
pelling UPEC, presumably as part of an innate defense (69).
Another potent innate defense is the exfoliation of umbrella
cells and influx of neutrophils (50). A mechanism used by
UPEC to combat these defenses is to escape into the cytoplasm
of superficial umbrella cells, where they are capable of rapidly
replicating into biofilm-like intracellular bacterial communities
(IBCs) comprised of 104 to 105 bacteria (1, 34). Upon IBC
maturation, bacteria detach from the IBC biomass, flux out of
the host cell into the bladder lumen, and spread to neighboring
cells forming next-generation IBCs (34, 38). Thus, IBC forma-
tion represents a mechanism by which invasion of a single
bacterium can result in rapid expansion of UPEC numbers in
the urinary tract leading to disease (1, 51). Upon resolution of
infection, the terminally differentiated umbrella cells are re-
placed through Bmp4-specific signaling, restoring the imper-
meable uroplakin barrier (53). In addition, bacteria can invade
the transitional epithelium beneath the umbrella cells, estab-
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lish a quiescent intracellular reservoir (QIR) and remain dor-
mant until they reemerge and potentially cause a recurrence
(52). Reemergence from a QIR could partially explain why
recurrent UTI is often caused by a strain identical to the
primary infection (65). Recent work has shown that this is a
common pathway among UPEC isolates (22), and evidence of
this pathway also has been observed in humans (64). The
regulatory mechanisms governing IBC development and dis-
persal in response to environmental cues are still unknown.
Despite many similarities among UPEC isolates, genomic
features that are unique to UPEC have not yet been identified.
Many studies have identified UPEC as a diverse class of E. coli
that have evolved multiple and redundant strategies to colo-
nize the urinary tract (75). These diverse genomes have been
acquired through horizontal gene transfer (HGT). HGT gen-
erates diversity between bacterial species and, through natural
selection, contributes to the evolution of bacterial species (16,
40, 66). In addition to genetic variability, newly acquired DNA
can enable adaptation to life in a specialized niche through
specific factors. The acquisition of DNA by HGT results in the
exchange of large regions of DNA called genomic islands (GIs)
between bacteria (31). GIs can be acquired in several ways: (i)
inheritance of a plasmid that can remain autonomous or re-
combine into the chromosome, (ii) integration of a lysogenic
phage into the chromosome, and/or (iii) insertion of a linear
DNA fragment into the chromosome usually by transposition
or recombination (14, 43, 70). Some GIs are referred to as
pathogenicity islands (PAIs). PAIs contain large genomic
DNA regions often greater than 20 kb that carry at least one
virulence gene, are inserted within or near tRNA genes, con-
tain direct repeats and mobility sequences, and can frequently
be identified by a differing GC content relative to the bacte-
rial genome (24). In addition, PAIs often do not represent
homogeneous pieces of DNA but can instead be mosaiclike
structures generated by a multistep process involving genomic
acquisition, loss, and rearrangement (25). Study of UPEC
PAIs has revealed that they encode numerous virulence fac-
tors, including pili and adhesins, toxins, hemolysins, and iron
uptake systems. Interestingly, these same virulence factors can
be plasmid or phage encoded on intestinal E. coli isolates.
Thus, UPEC PAIs could represent former plasmid-derived
sequences. In addition, UPEC PAIs carry many cryptic genes,
open reading frames (ORFs) of unrelated and even unknown
functions, and pseudogenes. A UPEC isolate, UTI89, carries a
large extrachromosomal element with many characteristics of
UPEC PAIs. This plasmid, pUTI89, has a high proportion of
pseudogenes generated by insertion events, ORFs homologous
to proteins of nonplasmid origin, and orthologs of enteroinva-
sive E. coli (EIEC) proteins found on a large virulence plasmid
(12). These features describe a UPEC PAI that has potentially
not yet incorporated into the genome, known as a “PAI pre-
cursor” (41). pUTI89 is approximately 114 kb and, like plasmid
F, contains the tra operon for conjugative transfer, as well as
genes associated with plasmid replication and inheritance.
Although UPEC strains can cause disease in the urinary
tract, they can also exist within the human intestinal tract as
part of the normal microbiota. Thus, UPEC strains are distinct
from the commensal E. coli residing in the gastrointestinal
tract in that they possess virulence factors enabling successful
transition to and colonization of the urinary tract (8). Factors
required for successful infection in addition to type 1 pili are
being extensively investigated (76). While studies have dem-
onstrated that additional adhesin systems, toxins, autotrans-
porters, iron acquisition systems, and other factors (reviewed
in reference 75) may be important in establishing infection,
there is also an abundance of unknown genes labeled as hy-
pothetical or assigned putative functions that may play a role in
virulence (32). Here, we studied the role of pUTI89 in the
virulence of UPEC. Regions of pUTI89 were shown to be
present in the majority of a panel of clinical isolates, suggesting
maintenance and transmission within the community. The ef-
fect of curing pUTI89 from strain UTI89 was investigated. We
found that pUTI89 is involved in an early feature of in vivo
infection, even though we could not detect any alterations in
growth, type 1 pilus expression and function, or biofilm forma-
tion in vitro in the absence of pUTI89. A region on pUTI89
encoding the cjr operon found in EIEC was implicated in this
early defect.
MATERIALS AND METHODS
Bacterial strains. E. coli UTI89 is a cystitis-derived isolate of serotype O18:
K1:H7 (51). UTI89 was used for all assays within the present study. A panel of
clinical isolates was used to identify the presence of pUTI89. This panel has been
previously described by Garofalo et al. (22).
Plasmid purification and PCR to assay for pUTI89. Bacterial cultures from 18
clinical isolates and UTI89 were incubated overnight at 37°C under shaking
conditions. Plasmid was purified similar to the Kado and Liu method (37). The
purified plasmid DNA was then used for PCR analysis. Using the sequence of
pUTI89, primers were designed to amplify regions around the plasmid. These
eight primer pairs were named A to H (Table 1). A primer pair amplifying ompA
was used as a control for genomic contamination. Standard PCR protocols were
used (33). PCR products were run on a 1% agarose gel, and bands were detected
by ethidium bromide staining. A band migrating the correct distance represented
a “” for that region of pUTI89.
UTI89 curing. Using the phage lambda red recombinase system (13), UP062
and UP063 encoding the stability operon were deleted from pUTI89 to make
UTI89/pUTI89UP062-63, creating a kanamycin-resistant UTI89. This mutant
of UTI89 was then cured of pUTI89 by ethidium bromide treatment. Curing was
done essentially as described by Bastarrachea and Willetts (4). Briefly, UTI89/
pUTI89UP062-63 was grown overnight in LB plus 50 g of kanamycin/ml.
Approximately 102 to 104 cells of the overnight culture/ml were inoculated into
flasks containing LB plus ethidium bromide (100, 90, 80, 70, 60, 50, 40, 30, 20,
and 10 g/ml), followed by shaking at 37°C for 16 h. Using the highest concen-
tration of ethidium bromide that sustained growth (based on visual turbidity), the
culture was diluted, plated onto LB agar plates, and grown overnight at 37°C.
Single colonies were picked from the LB agar plate and patched onto LB agar
plates containing 50 g of kanamycin/ml. Colonies sensitive to kanamycin were
grown overnight in LB and subjected to plasmid purification and PCR for
pUTI89 as described above. Cultures with no positive reactions in the PCR assay
were considered to be cured of pUTI89.
Growth curves. Bacteria were grown in LB at 37°C shaking overnight.
Cultures were diluted 1:1,000 into either LB or M9 minimal medium plus 10
g of niacin/ml, and 200 l was inoculated into a 96-well plate in triplicate.
A microplate reader running the SoftmaxPro program was used to read at
37°C every 20 min for 10 h with shaking at an optical density at 600 nm
(OD600). The data from each read was averaged and graphed to obtain the
growth curve.
Immunoblot assay for FimH and FimA. For immunoblot assays of FimH and
FimA expression, bacteria were grown statically in LB at 37°C for 24 h to obtain
optimal type 1 pilus expression. Equivalent numbers of cells (OD600  1.0) from
each isolate were suspended in sodium dodecyl sulfate (SDS) sample buffer, 1 M
HCl was added dropwise until a pH indicator (bromophenol blue) turned yellow,
and the solution was heated at 95°C for 5 min. The samples were then neutralized
with NaOH, analyzed by SDS-polyacrylamide gel electrophoresis, and trans-
ferred to nitrocellulose, followed by immunoblotting with primary antibodies to
either FimH or FimA (raised in rabbits using purified FimH or FimA protein,
respectively) and secondary antibody alkaline phosphate-conjugated anti-rabbit
whole-molecule immunoglobulin G. Specific FimH or FimA proteins were visu-
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alized on nitrocellulose membranes by using the BCIP/NBT liquid substrate
system (Sigma). Reactions were analyzed for intensity using ImageJ software
(http://rsb.info.nih.gov/ij/).
HA assay. Bacteria were grown for 24 h (as described in the immunoblot assay)
to induce expression of type 1 pili. Hemagglutination (HA) assays with guinea
pig erythrocytes were performed using well-established protocols (27). Briefly,
equivalent numbers of cells (OD600  1.0) from each isolate were suspended in
phosphate-buffered saline (PBS) or in PBS plus 2% mannose and added in
twofold dilutions to V-bottom 96-well plates (Costar). Guinea pig erythrocytes
were resuspended in PBS to an OD640 of 1.9 and added to the 96-well plate. The
plate was incubated at 4°C overnight. The HA titer was scored by the last well
with visible agglutination. An HA titer of 1 equals agglutination at a 1:2 dilution,
whereas an HA titer of 9 equals agglutination at a 1:512 dilution, indicating a
high level of type 1 pilus function.
Biofilm assay. Bacteria grown overnight in LB were diluted 1:1,000 into LB,
M9 minimal medium plus 10 g of niacin/ml, or YESCA broth and then added
to 96-well polyvinyl chloride microtiter plates. LB and M9 plus 10 g of niacin/ml
biofilms were grown at room temperature for 48 h, and YESCA biofilms were
grown at 30°C for 48 h. Plates were rinsed and stained with crystal violet and
quantified as described previously (56).
Mouse infections. Eight-week-old C3H/HeN (NCI) female mice were anes-
thetized by inhalation of isoflurane and infected via transurethral catheterization
with a 50-l suspension of 107 CFU of a given isolate. Bacteria for inoculation
were grown 24 h at 37°C statically. At the indicated times postinfection, mice
were sacrificed by cervical dislocation under anesthesia, and the bladders were
immediately harvested and processed as described below. All mouse infection
studies were approved by the Animal Studies Committee of Washington Uni-
versity.
Tissue bacterial titer determination. To enumerate the bacteria present, blad-
ders were aseptically harvested at 6, 24, or 48 h or 1 or 2 weeks postinfection;
homogenized in PBS; serially diluted; and plated onto LB agar plates. The CFUs
were enumerated after 16 h of growth at 37°C.
Gentamicin protection assay. To enumerate the bacteria present in the intra-
cellular versus extracellular compartments, bladders were aseptically harvested
at 1 and 6 h postinfection. The bladders were then bisected twice and washed
three times in 500 l of PBS each. The wash fractions were pooled, lightly spun
at 500 rpm for 5 min to pellet exfoliated bladder cells, serially diluted, and plated
onto LB agar to obtain the luminal fraction. The bladders were treated with 100
g of gentamicin/ml for 90 min at 37°C. After treatment, the bladders were
washed twice with PBS to eliminate residual gentamicin, homogenized in 1 ml of
PBS, serially diluted, and plated onto LB agar to obtain the intracellular fraction.
The CFUs were enumerated after 16 h of growth at 37°C.
Confocal scanning laser microscopy. To visualize bacterial behavior within
the bladder, bladders were aseptically harvested at 6 h postinfection. Blad-
ders were bisected and pinned open revealing the luminal surface. The
splayed bladders were then incubated for 20 min at room temperature with (i)
Alexa Fluor 488-conjugated wheat germ agglutinin (WGA; 1:1,000 in PBS;
Molecular Probes) to stain the bladder luminal surface and (ii) nucleic acid
dye SYTO61 red (1:1,000 in PBS; Molecular Probes) to stain bacteria and
bladder epithelial cell nuclei. Trolox (10 M; Fluka) was added to the splayed
bladders to reduce photobleaching (67). Bladders were examined with a Zeiss
LSM 510 Meta laser scanning inverted confocal microscope using a 63 oil
immersion objective lens. WGA and SYTO61 were excited at 488 and 633 nm,
respectively.
Enumeration of IBCs. To accurately count the number of IBCs, bladders were
aseptically harvested at 6 h postinfection, bisected, splayed on silicone plates, and
fixed in 2% paraformaldehyde. IBCs, readily discernible as punctate violet spots,
were quantified by LacZ staining of whole bladders (36).
Statistical analysis. Observed differences in bacterial titers and IBC numbers
between isolates were analyzed for significance by using the nonparametric
Mann-Whitney U test (Prizm; GraphPad Software).
Microarray. UTI89 and pUTI89 were inoculated into LB broth and grown
for 24 h at 37°C statically. After 24 h of growth, bacteria were diluted 1:1,000
into fresh LB and grown for an additional 24 h at 37°C statically. RNA was
isolated by using an RNeasy minikit (Qiagen). Contaminating DNA was
removed from all RNA samples by treating with DNase I for 1 h at 37°C.
RNA samples were converted to cDNA, biotinylated, and hybridized to gene
chip arrays as described for prokaryotic sample and array processing (Af-
fymetrix). The custom array was designed using ORFs of E. coli UTI89,
CFT073, and K-12 strains and enterohemorrhagic E. coli (EHEC) strains
(available sequences at the time of design), resulting in 20,462 sequences. The
Affymetrix GeneChip is named UTI89-01a520299F and contains 98.7%
(4,977 of 5,044) of the UTI89 chromosome genes and 77.9% (113 of 145) of
the pUTI89 plasmid genes. The data were analyzed according to recommen-
dations from analysis of the Golden Spike data set (58), using multi-mgMOS
(see reference 14 in reference 58) for summarization, all genes for the
post-summarization Loess normalization, and the probability of positive log
ratio (PPLR; see reference 13 in reference 58) to identify differentially
expressed genes. A cutoff of 0.95 was used as a threshold for the PPLR test.
TABLE 1. Primers for plasmid PCR
Gene Primer sequence (5	–3	) Primer name Size ofproduct (bp)
Primer coordinate
positiona
scsD CATACGCTGGACGGGGAAAC A-forward 143 4384
GACGCTCTCCCCTTCCGACT A-reverse –4527
senB GCAGATTCGCGTTTTGAGCA B-forward 302 25705
CGGATCTTTCAACGGGATGG B-reverse –26006
guaA CCCGTAGTGGGGGTGTTGAG C-forward 375 49081
GCCCCTGCCACCTACCTTCT C-reverse –49456
Transposase GCTTCGGGAACGCTGTAACG D-forward 414 60645
AGAAGGCTGCGGTGCTGAAG D-reverse –61059
ycfA CGCCTGGTGGTGAAGGAAAG E-forward 236 64115
GACCACCTCCCGCAGAACAC E-reverse –64351
UP100, UP101 TGGGGGCTGAAAACCAGAGA F-forward 531 75326
ACCGAAGGCACGAACTGCAT F-reverse –75857
traU TTCCTTCTCGCCGGTCATGT G-forward 111 89649
CCAGCGAGAGCGGGAAAATA G-reverse –89760
traI GCGATGCGGTCAGTGTTCTG H-forward 190 106531
GGACAGCCGTTCATCCTGCT H-reverse –106721
a GenBank accession no. NC_007941.
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UTI89 contains a plasmid with characteristics of a PAI
precursor. Many E. coli strains possess extrachromosomal ge-
netic elements carrying genes encoding for a DNA transfer
apparatus. These elements include the conjugative plasmids F
and R100. Pathogenic E. coli often possess plasmids, such as
pO157 in EHEC isolates, that contain genes encoding for
putative virulence factors such as toxins, type III secretion
systems, and/or adhesive organelles (9, 44). Many studies have
demonstrated the involvement of these plasmids in EHEC
pathogenesis (5, 39, 71, 72); however, the role of UPEC plas-
mids has not been well studied.
UTI89 contains an epichromosomal genetic element of
114,230 nucleotides (12). This plasmid can be divided into two
major portions based on its homology with other E. coli plas-
mids. One half of the plasmid contains genes involved in plas-
mid replication and conjugative DNA transfer similar to those
on Plasmid F, an archetypical conjugative plasmid. A large
number of ORFs on the other half of pUTI89 show homology
(
70% at the amino acid level) to genes present on plasmids
carried by pathogenic strains of E. coli (Fig. 1). Three pUTI89
ORFs were identified to be orthologs of EIEC O164 cjrA, cjrB,
and cjrC genes (68). Expression of these genes in EIEC ap-
pears to be negatively regulated by iron and positively regu-
lated by temperature via VirB. A putative iron regulation fur
box is located upstream of pUTI89 cjrA (nucleotides 21010 to
21028) similar to what is seen with their orthologs in EIEC
O164 plasmid. UTI89 CjrB is homologous to the TonB protein
present in many Gram-negative bacteria, which is thought to
be involved in energy transduction between the inner and
outer membrane (60). CjrB appears to be an EIEC-specific
TonB protein homolog, since E. coli tonB strains without cjrB
were not sensitive to colicin Js.
Likewise, UTI89 CjrC shows homology to putative outer
membrane siderophore receptors. Similar to the EIEC O164
large virulence plasmid, pUTI89 possesses the senB gene, en-
coding an enterotoxin, downstream of and partially overlap-
ping the cjrC gene. In the EIEC strain, EI34, the SenB gene
product was demonstrated to account for at least 50% of the
enterotoxic activity (55).
Six pUTI89 ORFs also showed high identity to genes located
on the UTI89 chromosome. Four of these were either trans-
posases or hypothetical proteins of unknown function. Two
other ORFs, UP042 and UP043, are homologous to genes
predicted to possess membrane transport functions. UP042
exhibited 100% amino acid identity to a gene encoding a com-
ponent of a putative ABC transporter that is also found in
UPEC strains F11 and UMN026. UP043 was 95% identical at
the amino acid level to an outer membrane heme receptor
encoded by the UTI89 chromosome. Similar to their counter-
parts on the plasmid, the two homologs to UP042 and UP043
in the UTI89 genome (UTI89_C1129 and UTI89_C1130) were
also adjacent to each other on the chromosome. Two trans-
posases adjacent to one another on the plasmid, UP040 and
UP041, also had homologs (UTI89_C2257 and UTI89_C2258)
on the chromosome. However, whereas these two sets of ORFs
were located near each other on the plasmid, their homologous
sets were over 1 Mb apart on the chromosome. It is unclear
whether these genes were acquired separately or as a result of
a gene duplication event.
Several ORFs within pUTI89 are homologous to sequences
encoding proteins of nonplasmid origin in the database. These
were scsCD (Salmonella enterica serovar Typhimurium LT2),
nqrC (sodium-translocating NADH dehydrogenase [ubiqui-
none] gamma subunit [V. cholerae]), and iron transporters (pu-
tative membrane protein and putative periplasmic protein [Y.
pestis]). Acquisition of these genes likely occurred through
evolution of the plasmid, suggesting that pUTI89 is a hot spot
for recombination and genetic exchange. Furthermore, many
pseudogenes were present on the plasmid as the result of gene
disruption by insertion and deletion (12). The presence of gene
homologs from pathogenic bacteria and the fluid nature of the
plasmid genome argue that pUTI89 may be a PAI precursor
and thus play an important role in UTI pathogenesis.
pUTI89 in UPEC clinical isolates. We sought to determine
whether pUTI89 and/or its genes were common among UPEC
isolates since strong selection to maintain the plasmid by hu-
man strains suggests importance in pathogenesis. We have
previously characterized a panel of UPEC clinical isolates (22).
This panel of 18 isolates was isolated from women and encom-
passes all clinical syndromes of UTI and thus is thought to be
a representative pool of UPEC strains (22). Extrachromosomal
DNA was purified from each of these strains and PCR ampli-
fication of eight regions on pUTI89 was used to assess its
presence in the clinical isolates (Table 2). Of the 18 isolates, 6
(33%) had all eight regions of pUTI89, suggesting the presence
of the entire plasmid, and 5 (28%) had no evidence of pUTI89.
Genomic DNA was purified from the five isolates that had no
positive PCRs for pUTI89 to determine whether these regions
were present on the chromosome. All PCRs were still negative,
suggesting these isolates also did not have plasmid genes on
their chromosome. Of the 13 isolates that had evidence of
pUTI89 (72%), 100% of them had the regions containing ycfA
and UP100 and UP101, all of which are hypothetical proteins.
This would suggest that these proteins are an important char-
FIG. 1. pUTI89 diagram. pUTI89 can be divided into two major
portions. One half contains genes involved in conjugative DNA trans-
fer (in blue), and the other half contains genes present on plasmids
from pathogenic E. coli and other pathogenic bacteria, as well as genes
encoded chromosomally in other bacteria (in red). Indicated next to
each region is the gene name, organism it is also found in, and/or the
operon function.
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acteristic of pUTI89 since they are most commonly maintained
in human UPEC isolates. Furthermore, the prevalence of
pUTI89 regions within this panel of clinical isolates (72%)
suggests its involvement in pathogenesis within the urinary
tract. It is possible that the regions identified within the clinical
isolates were a reflection of small amounts of genomic con-
tamination in the plasmid preparation and would thus repre-
sent chromosomal genes. However, that these regions are still
maintained in the population is evidence of their importance.
Deletion of pUTI89. We sought to eliminate pUTI89 from
UTI89 and subsequently assess the effect of the loss of the
plasmid on pathogenesis as well as in a panel of in vitro assays.
Traditional ways of eliminating a plasmid from its host involve
intercalating dyes, DNA gyrase inhibitors, rifampin, and SDS,
whereas more advanced ways use transposon-based elimina-
tion (30) and SacB curing (29). pUTI89 did not respond to any
of the above methods and was thus not successfully eliminated
from UTI89 using any of these approaches. We noted that
pUTI89 contains an stb locus with 63% homology to StbA of R
plasmid NR1 (49). In NR1, StbA is involved in the partition of
plasmid molecules to daughter cells during cell division and is
therefore essential for stable plasmid inheritance. Mutations
that inactivate stb function result in plasmid instability, so that
plasmid-free cells are segregated at a rate consistent with ran-
dom distribution of plasmid copies at cell division (48). We
therefore deleted the stbAB genes from pUTI89 using the 
red recombinase system (13). After deletion, pUTI89 was not
spontaneously lost so UTI89/pUTI89stbAB was then sub-
jected to curing by an intercalating dye, ethidium bromide. At
a concentration of 90 g of ethidium bromide/ml, the plasmid
was eliminated from UTI89; this was confirmed by selective
plating and PCR (Fig. 2). Thus, it required both gene manip-
ulation and a traditional curing method to delete pUTI89 from
UTI89.
Deletion of pUTI89 has no in vitro effects. The effect of
curing UTI89 of pUTI89 on growth under different conditions,
pilus expression, and biofilm formation was first evaluated in a
series of in vitro analyses. UTI89 and pUTI89 grew equally
well in both rich media (LB) and minimal medium (M9 plus 10
g of niacin/ml), suggesting that, under these conditions, the
plasmid is not essential for bacterial growth (Fig. 3A). Type 1
pili are an essential virulence factor to UTI89 in vivo (76); thus,
we investigated whether the expression of the fim operon was
altered by removal of pUTI89. An immunoblot with anti-FimH
and anti-FimA antisera showed no difference in expression
levels of either protein in UTI89 versus pUTI89 bacteria
(Fig. 3B). Since expression does not necessarily confirm func-
tion, the pili were tested for their ability to agglutinate guinea
pig red blood cells. HA titers were analyzed in the presence or
absence of mannose to confirm that agglutination was a spe-
cific measurement of type 1 pilus function. Both strains had
equal mannose-resistant and mannose-sensitive HA titers, sug-
gesting that pUTI89 is not involved in type 1 pilus expression
or function (Fig. 3D). Previous work has shown that UTI89
forms type 1 pilus-dependent biofilms during growth in LB and
curli-dependent biofilms during growth in YESCA (11). Fur-
FIG. 2. Confirmation of pUTI89 curing by PCR. pUTI89 was cured
from UTI89 by ethidium bromide treatment. Plasmid purification,
followed by PCR with primer pairs A to H, was used to identify
plasmidless strains. UTI89 with intact pUTI89 (top panel) reveals a
banding pattern as observed with very little genomic contamination, as
evidenced by the ompA band. PCR of the plasmid-cured strain (bot-
tom panel) revealed no positive PCR confirming the elimination of
pUTI89.
TABLE 2. Evidence of pUTI89 in a panel of clinical isolatesa
Strain

















ASB1        
ASB2        
ASB3        
ASB4        
ASB5        
acute1 – – – –    –
acute2 – – – – – – – –
acute3 – – – – – – – –
acute4 – – – – – – – –
rUTI1 – – – – – – – –
rUTI2 – – – –   – –
rUTI3 –  – –   – –
rUTI4        
rUTI5 – – – –    
pyelo1 – –      –
pyelo2 – – – – – – – –
pyelo3 –  –     
pyelo4 – – – –    –
UTI89        
a Gene descriptions and percent prevalences: scsD, secreted copper-sensitivity
suppressor D, 33.3%; senB, enterotoxin TieB protein, 44.4%; guaA, hypothetical
protein, 38.9%; transposase, transposase for insertion sequence element IS21,
44.4%; ycfA, hypothetical protein, 72.2%; UP100/UP101, hypothetical proteins,
72.2%; traU, F pilus assembly protein, 61.1%; traI, DNA helicase I, 44.4%.
Primer pairs A to H are described and defined in Table 1.
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thermore, F plasmids have been shown to promote biofilm
formation in a K-12 genetic background during growth in min-
imal media (23). Thus, the ability of UTI89 and pUTI89 to
form these various types of biofilms in vitro was evaluated. In
both rich medium (LB) and minimal medium (M9 plus 10 g
of niacin/ml), pUTI89 formed biofilms identical to wild-type
UTI89 (Fig. 3C). Biofilm formation during growth in YESCA
medium at 30°C was also equivalent between the two strains
(Fig. 3C). Thus, pUTI89 has no effect on general growth, pilus
expression or function, or curli expression or function.
pUTI89 is important for early infection. We sought to de-
termine whether the loss of pUTI89 could have affected the
virulence of UPEC in a way that was not measurable by the in
vitro tests. Thus, in vivo fitness was assessed in the UTI mouse
model. In this infection model, UTI89 as well as multiple
clinical isolates proceed through an IBC pathway during the
acute stages of infection (1, 22, 34). Thus, C3H/HeN mice
were inoculated with 107 of either UTI89 or pUTI89, and
the bacterial burden was evaluated at different times postin-
fection in order to determine whether the plasmid played a
role in infection. At 6 h postinfection the bacterial load of
pUTI89-infected bladders was significantly lower (P 
0.0001) than that of UTI89-infected bladders (Fig. 4A). To
minimize the possibility that a secondary mutation contributed
to the attenuation, additional clones of pUTI89 were con-
structed independently, and they were also found to have a
significant defect in titers at 6 h postinfection (Fig. 4B). Nev-
ertheless, by 24 h postinfection, pUTI89 titers were compa-
rable to UTI89 and remained that way through the entirety of
the time course. These data suggest that genes on pUTI89 may
be involved in the acute stages of infection.
pUTI89 is important for intracellular infection. Due to the
significant defect during early infection of the pUTI89 strain
despite equivalent in vitro type 1 pili expression, we assessed
the bacteria’s ability to bind to and invade the urothelium in
vivo. Bladders from 1 and 6 h infected C3H/HeN mice were
removed, and both the intracellular and the luminal popula-
tions were enumerated. Luminal bacteria were defined as the
bacteria that were washed from the bladder after removal.
Bladders were then treated with gentamicin to kill any residual
extracellular bacteria, followed by rinsing. Homogenates of the
treated bladders were then plated to enumerate surviving in-
tracellular bacteria. At both 1 and 6 h postinfection, significant
decreases in both the luminal and the intracellular populations
of pUTI89 were observed relative to UTI89 (Fig. 5). These
results suggested that pUTI89 may be involved in enhancing
binding, invasion, extracellular survival, and/or aiding in im-
mune evasion. In order to gain more insight into these results,
we investigated whether we could visually observe a diminished
invasion or reduced extracellular colonization by confocal mi-
croscopy. At 6 h postinfection, UTI89- or pUTI89-infected
bladders were removed, splayed, and stained. Examination by
confocal microscopy revealed that pUTI89-infected bladders
had fewer IBCs (Fig. 6) and little to no observable extracellular
bacteria compared to its wild-type-infected counterpart.
UTI89-infected bladders had numerous extracellular bacteria,
many in filamentous morphology. In an effort to more accu-
rately enumerate IBCs, we performed LacZ staining on
UTI89- and pUTI89-infected bladders. This quantification
revealed a significant defect in the number of IBCs observed
FIG. 3. In vitro characteristics of pUTI89. Plasmid-cured UTI89
behaved identically to UTI89. (A) Growth of UTI89 and pUTI89
were equivalent in LB broth (solid line) and M9 plus 10-g/ml niacin
broth (dashed line). (B) Type 1 pili expression based on FimH and
FimA immunoblots was equivalent in both strains. Densitometry anal-
ysis was used to quantify the bands observed (ImageJ software).
(C) Biofilm formations under type 1-dependent and curli-dependent
conditions were indistinguishable in UTI89 versus pUTI89. (D) Both
UTI89 and pUTI89 exhibited equal mannose-sensitive HA titers,
indicating equal expression levels and functionality of type 1 pili.
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between the two isolates (Fig. 6). These data are consistent
with the results from the gentamicin protection assay and iden-
tifies pUTI89 as a potential mediator of binding and invasion,
extracellular survival, and/or host evasion at the early stage of
infection.
Identification of virulence factors on pUTI89. Deletion of
pUTI89 alters UTI89’s behavior in vivo. In an attempt to de-
cipher which region of pUTI89 is responsible for this observed
phenotype, we eliminated regions of the plasmid and examined
their effects in the mouse UTI model. Regions were selected
for deletion based on their annotation and/or their upregula-
tion upon growth in urine relative to growth in LB (data not
shown). Table 3 specifies the gene, size, and predicted function
of the regions chosen for deletion. A total of 23.5 kb was
deleted from pUTI89, resulting in nearly one-fourth of the
plasmid. Each of the constructed deletions was individually
inoculated into the mouse, and the bacterial load was evalu-
ated at 6 h postinfection. Of the seven deletions made, two had
a significant decrease on bacterial load relative to UTI89 at 6 h
postinfection (Fig. 7). These mutants were UP028-30 and
UP062-63. UP062-63 has a 1.4-kb region deleted encoding
for the stbA and stbB genes of the stability operon. These genes
are involved in maintenance of the plasmid. The reduction in
bacterial titers upon deletion of stbAB presumably reflects the
plasmid instability and is consistent with the results seen with
the pUTI89 mutant (Fig. 3); when pUTI89 is not successfully
maintained in vivo, the bacterial infection is reduced.
UP028-30 has a 4.7-kb region deleted encoding for cjrB, cjrC,
and senB. The cjr operon (for colicin Js receptor) encodes for
proteins that have been described to be involved in colicin Js
uptake (68). However, their function in UTI89 is unknown.
UP028-30, however, was not as severely attenuated as
pUTI89, which suggests that other genes on pUTI89 may also
be important during UTI pathogenesis. This study shows that
pUTI89 is used to acquire important virulence factors for the
early stage of infection. Further work will be required to un-
derstand the role of these operons in early infection. Studies
are currently under way to examine the expression patterns of
the cjr and sen loci and their impact on UTI pathogenesis.
DISCUSSION
Virulence in Enterobacteriaceae has been associated with the
acquisition of large plasmids that confer distinguishing pheno-
FIG. 4. In vivo time course of UTI89 and pUTI89. (A) pUTI89 tested in our mouse model of UTI revealed a significant decrease in bladder
colonization at 6 h postinfection compared to wild-type UIT89 (P  0.0001 [Mann-Whitney]). However, by 24 h postinfection and beyond,
colonization was equivalent in both strains. (B) Additional clones of pUTI89 confirmed that the defect was due to the loss of pUTI89 and not
additional mutations within the genome (P  0.001 by Mann-Whitney).
FIG. 5. Colonization and invasion of UTI89 versus pUTI89. Gentamicin protection assays performed at 1 and 6 h revealed a significant
decrease in both the extracellular (luminal) and intracellular population for pUTI89. A more significant decrease in luminal colonization with
pUTI89 was observed at 6 h postinfection (P  0.001 [Mann-Whitney]).
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typic pathogenic traits. These virulence plasmids are generally
low copy number, are approximately 60 to 200 kb in size, and
are usually similar to F plasmid or R100 plasmid (74). Viru-
lence plasmids in species of enteropathogenic E. coli (EPEC),
enterotoxigenic E. coli, and enteroaggregative E. coli are large
F-like plasmids that typically encode different fimbrial adhesins
that facilitate characteristic modes of colonization of intestinal
epithelia (54). The presence of these F-like virulence plasmids
in UPEC has been largely unstudied. Generally, it is thought
that virulence genes involved in UPEC colonization are en-
coded on the chromosome instead of a virulence plasmid.
However, a UPEC isolate, UTI89, carries a large F-like plas-
mid, pUTI89, similar to typical Enterobacteriaceae plasmids, in
which approximately half of the plasmid encodes genes of
unknown function and/or virulence-associated genes. It was
recently discovered that a plasmid, pEC14_114, which is nearly
identical to pUTI89, seems to be widely present in cystitis-
causing UPEC strains, suggesting that it might contribute to
UPEC virulence and/or fitness (15). We investigated the role
of pUTI89 as a virulence plasmid and discovered that pUTI89
conferred a fitness advantage upon UTI89 in the acute stages
of infection.
UTI89 was cured of the pUTI89 plasmid, creating the re-
sulting strain, pUTI89.  differences were observed be-
tween pUTI89 and UTI89 in growth kinetics, type 1 pilus
formation, or biofilm formation in vitro. However, we hypoth-
esized that genes present on pUTI89 that encode hypothetical
proteins or other virulence-associated factors could provide a
fitness advantage in vivo that would not necessarily have been
detected in our limited in vitro analysis. Chlamydia trachomatis
contains a plasmid in which no observable phenotype has been
identified in vitro; however, in the absence of the plasmid, C.
trachomatis was significantly attenuated and failed to accumu-
late glycogen in vivo (10). The defect was partially attributed to
plasmid-dependent regulation of multiple chromosomal genes.
Plasmid control of chromosomally encoded genes has also
been observed in Yersinia pestis, EPEC and Bacillus anthracis
(3, 7, 59). Thus, we performed a microarray analysis after
growth in static LB in order to compare gene expression of
UTI89 versus pUTI89. A total of 76 plasmid genes were
differentially detected in the presence of pUTI89, including the
genes within the tra operon, arguing that these genes are ex-
pressed in vitro under these conditions. In addition, altered
regulation of 14 chromosomal genes was observed in the ab-
FIG. 6. Confocal microscopy and LacZ staining for IBCs. Mice
were infected with UTI89 or pUTI89 and bladders were harvested at
6 h postinfection, splayed, and stained with WGA (bladder surface in
green) and SYTO61 (bacteria in red). Confocal microscopy revealed
IBC formation in bladders infected with either isolate. However, ex-
tensive filamentation was only observed in wild-type UTI89. IBCs were
quantitated by LacZ staining revealing a significant defect (P  0.001
[Mann-Whitney]) in the number of IBCs observed in pUTI89-in-
fected bladders.
TABLE 3. Directed deletions of pUTI89 regions
Gene
annotation Size (kb) Gene name Function
UP007-UP014 8.4 scsC, scsD Secreted copper-sensitivity suppressor, Yersinia export
UP015-UP017 1.6 ABC transporter, ATP-binding protein, putative thioredoxin-family protein
UP028-UP030 4.7 cjrB, cjrC, senB Colicin Js sensitivity protein and outer membrane receptor, enterotoxin
UP042-UP046 6.8 Hemin receptor, serine-threonine protein kinase
UP062-UP063 1.4 stbA, stbB Stable plasmid inheritance proteins
UP095 0.4 psiB Regulator of SOS induction
UP145 0.2 hmo Putative regulator
FIG. 7. Identification of virulence factors on pUTI89. Regions on
pUTI89 were deleted by using the lambda red recombinase system.
Deletions encompassing UP028-30 and UP062-63 (E) resulted in a
significant reduction in bacterial load at 6 h postinfection (P  0.05
and P  0.0001 [Mann-Whitney], respectively). UP062-63 encodes the
stability operon, and UP028-30 encodes the cjr operon.
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sence of pUTI89, suggesting that pUTI89 influences the reg-
ulation of multiple chromosomal genes. However, the majority
of these genes are hypothetical and will require further analysis
(Table 4).
We have demonstrated that pUTI89 provides a fitness ad-
vantage to UTI89 in the acute stages of infection. We observed
a significant reduction in luminal colonization, invasion and
IBC formation from 1 to 6 h postinfection (Fig. 5 and 6). At the
inoculation sizes used in the present study (107 bacteria/blad-
der) no significant differences in CFU per bladder were seen at
later time points. Thus, under these conditions, pUTI89 was
attenuated in the acute stages but was later able to reach a
colonization threshold that allowed it to establish an infection
in the bladder. However, under more severe selection pres-
sures, difficult to recapitulate in the laboratory, such as a much
smaller inoculum size or ascension from the fecal flora to the
urinary tract, fitness advantages in the acute stages would most
likely impact the long-term outcome of disease.
Selective deletions of operons on pUTI89 revealed that the
cjr operon may be playing a role in infection. The operon
contains three proteins; however, it was shown that only CjrB
and CjrC are essential for colicin Js sensitivity. The CjrC pro-
tein of UTI89 is 99% identical to that of EIEC O164. However,
it was shown that despite the similarity of CjrBC proteins to
gene products of other strains, no bacterial strains other than
EIEC and Shigella were found to be sensitive to colicin Js.
Future experiments to test whether UTI89 is sensitive to coli-
cin Js will identify whether these proteins perform a similar
function in UTI89. CjrC is homologous to a putative outer
member siderophore receptor, and a fur box is located up-
stream of this operon, suggesting that it is regulated by iron.
Iron is an essential cofactor of many enzymes and bacteria
require iron concentrations at around 107 to 105 M to
achieve optimal growth. The level of free iron is estimated to
be very low in the environment and biological fluids (1018 M)
(2). Bacteria have evolved strategies to acquire iron seques-
tered by the host in order to survive in specific niches and
consequently cause infections. Thus, iron acquisition for the
survival of UPEC within the urinary tract is critical (26, 61, 73,
78). UPEC typically contains three to five iron acquisition
systems, whereas fecal/commensal isolates contain two to three
iron-related operons, suggesting that the redundancy in these
systems may provide a competitive advantage to UPEC within
the urinary tract (42). In addition, strong preferential expres-
sion of yersiniabactin and salmochelin have been observed
among urinary strains compared to fecal strains from same
patient studies (26). Reigstad et al. showed that in the absence
of chuA there is a significant decrease in IBC size but not an
elimination of IBCs (61). Given our results, we propose that
the cjr operon is important for iron acquisition; however, it is
not essential due to the redundancy of iron acquisition systems
within UTI89. Work is currently under way to elucidate the
role of Cjr proteins in the early stages of infection.
Strong selection for UTI89 to maintain pUTI89 provides a
compelling argument for its importance in pathogenesis. Large
plasmids impose a significant metabolic burden on the bacteria
and, in the absence of selection, may be lost from the host in
spite of plasmid maintenance systems that are assumed to
prevent loss (74). pUTI89 has two prominent features: the
presence of the tra operon involved in DNA transfer and the
presence of virulence-associated genes homologous to those
found on other pathogenic plasmids, in other organisms. Plas-
mid transfer via conjugation is an important mechanism for
DNA exchange or dissemination and accelerates the evolution
of bacterial pathotypes (24). The presence of the tra operon
allows pUTI89 to be maintained and disseminated to other
UPEC strains and Enterobacteriaceae. In addition, the large
virulence plasmid can serve as a genetic hot spot where extra-
chromosomal DNA can be freely acquired without disrupting
essential genes. The plasmid, pUTI89, may facilitate the free
exchange of DNA between the symbiotic gut bacteria. The
presence of the cjr operon on pUTI89, as well as on a virulence
plasmid, in EIEC supports this hypothesis. Presumably, genes,
such as cjr, that increase fitness in the bladder may be selected
upon introduction of the bacteria into the urinary tract. This is
supported by our observation that 44% of our tested isolates
demonstrated the presence of this operon either within a plas-
mid or on the chromosome.
The presence of pUTI89-like plasmids is widespread in
UPEC strains (15) and could serve multiple roles, allowing for
efficient incorporation of foreign DNA without disruption of
essential genes. Plasmid stability genes ensure newly acquired
genes are replicated without the strong selective pressure of a
bladder environment, whereas a functional tra operon allows
for conjugation and dissemination of these genes to other
UPEC strains and Enterobacteriaceae. All of these activities
provide UPEC with a broad arsenal of proteins, some of which
are necessary for colonization of the bladder. Due to the lack
of constant selective pressure, UPEC strains have evolved mul-
tiple strategies for colonization of the bladder, resulting in the
diverse genomes of UPEC strains seen today. The pUTI89
plasmid, with maintenance and stability machinery, may have
facilitated the acquisition and incorporation of extrachromo-
somal DNA without disrupting essential cellular pathways and
provided a mechanism that selected for genes that increased
fitness in the bladder. This constant evolution has allowed
TABLE 4. Chromosomal genes demonstrating a 2-fold transcript






Hypothetical YfaQ precursor UTI89_C2508 –43.3
Hypothetical UTI89_C3244 –23.2














a Gene transcripts passing all statistical and quality tests performed as de-
scribed in Materials and Methods.
b Change in pUTI89 signal compared to UTI89 signal.
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UPEC to acquire multiple and redundant mechanisms to
adapt and thrive in the urinary tract environment, explaining
why, despite the well-studied nature of UPEC, especially in
regard to virulence factors and colonization strategies, no sin-
gle feature accurately defines an isolate as UPEC (45). Instead,
UPEC contains a mosaic genome that is the result of genomic
acquisition, loss, and rearrangement.
It remains unclear as to when, evolutionarily, pUTI89 was
acquired and to what extent it helped shape the landscape of
the UTI89 genome by acting as a midway point for virulence
gene incorporation into the genome. We discovered that the
presence of pUTI89 increases the ability of UTI89 to invade
and colonize the bladder. Further investigations will examine
how less virulent strains without pUTI89 are influenced by its
addition. Examining a gain of function in less-virulent strains
could help elucidate at what stage(s) pUTI89 virulence genes
function. In addition, characterizing plasmids and genes from
different UPEC will facilitate our understanding of the mech-
anism of virulence and the evolution of UPEC and aid in the
design of efficacious strategies to fight UTI.
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